Question-and-Answer SessionWell, maybe just to start off, would you like to share some opening thoughts on Alnylam for those who are a little bit less familiar?Jeffrey PoultonCFO & Executive VP Sure. We're a company that pioneered a new class of medicine called RNAi therapeutics. It's been a 20-plus-year journey for the company. There was a lot of work, probably for the first 10-plus years around delivery. But once the company figured out delivery, there's really been a steady cadence of progress. And wher ...